ENHANCING CHEMOIMMUNOTHERAPY FOR COLORECTAL CANCER WITH PACLITAXEL AND ALANTOLACTONE VIA CD44-TARGETED NANOPARTICLES: A STAT3 SIGNALING PATHWAY MODULATION APPROACH

Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach

Chemoimmunotherapy has the potential to enhance chemotherapy and modulate the immunosuppressive tumor microenvironment by activating immunogenic cell death (ICD), making it a promising strategy for clinical application.Alantolactone (A) was found to augment the anticancer efficacy of paclitaxel (P) at a molar ratio of 1:0.5 (P:A) through induction

read more